Compare Celsius Holdings, Inc. (CELH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Celsius Holdings, Inc. vs Sana Biotechnology Inc — how do they compare? Celsius Holdings, Inc. trades at $27.65 (market cap $7.11B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Celsius Holdings, Inc. is far larger — about 6.3× Sana Biotechnology Inc's market cap, and Sana Biotechnology Inc is trading nearer its 52-week high, Celsius Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| CELH | SANA | |
|---|---|---|
Market Cap | $7.11B | $1.13B |
Sector | Consumer Staples | Health |
52-Week High | $64.86 | $5.92 |
52-Week Low | $23.77 | $2.68 |
Enterprise Value | $8.90B | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CELH trades at $27.48, up 0.99% on the day, but remains under bearish technical pressure with key resistance at $29. The company reported Q2 2026 earnings that missed expectations, with revenue growth slowing to 11% year-over-year as core brand sales weakened, though Alani Nu and Rockstar acquisitions provided some offset. Net cash flow was negative $350.20 million in 2025 due to significant investing activities.
Outlook is mixed; strong analyst buy consensus (95.65%) and a $44.08 price target suggest long-term confidence in growth via PepsiCo partnership, but near-term risks include execution challenges, margin pressure, and ongoing investigations into management disclosures. The stock's high P/E of 122.13 reflects growth expectations that must materialize to justify valuation.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Celsius Holdings, Inc.
Celsius Holdings Inc engages in the development, marketing, sale, and distribution of functional calorie-burning beverages. It offers flavors including cola, orange, wild berry and lemon iced tea and non-carbonated flavors such as Raspberry Acai Green Tea and Peach Mango Green Tea under the Celsius brand name. The company distributes its products through direct-store-delivery distributors, as well as directly to retailers across various retail segments, including supermarkets, convenience stores, drug stores, nutritional stores, mass merchants, health clubs, spas, gyms, military, and e-commerce websites.
Read more on CELH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
